ARCHIVES

Cediranib/Olaparib Combination Nearly Doubles PFS in Phase II

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: Use More Ad Hoc Committees For Grants, Look At Number, Distribution Of Centeres: Katterhagen

August 28, 1981

Test May Identify Predictors For Recurrence Post-Surgery

January 28, 2011

Study: Ibrutinib Lowers IgM, Bone Marrow Disease Burden

July 26, 2013

IOM Recommends FDA Consolidate Each Drug’s Lifetime History

May 4, 2012

Bill Pressures HCFA To Launch Project On Reimbursement for Cancer Trials

July 26, 1996

NCI-Approved Clinical Trials

April 26, 2002